Constrained β-alanine based GpIIb/IIIa antagonists
摘要:
The concepts of centrally constrained and peptide based fibrinogen receptor antagonists have been successfully combined into a single series of analogs which have been demonstrated to be potent inhibitors of platelet aggregation. (C) 1997 Elsevier Science Ltd.
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).
[EN] COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
申请人:PTC THERAPEUTICS INC
公开号:WO2020231977A1
公开(公告)日:2020-11-19
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I), Formula (II), or Formula (III), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
this paper, we describe the synthesis of some endomorphin-1 based tetrapeptides in which a residue of the sequence Tyr-Pro-Trp-PheNH2 is replaced by the corresponding beta-isomer. These novel peptides showed different affinities for the opioid receptors labeled with [3H]-DAMGO in rat brain membranes, depending on the beta-amino acid. In particular, the tetrapeptide containing beta-Pro (Tyr-beta-(R)-Pro-Trp-PheNH2)
[EN] COMPOUNDS AND METHODS FOR MODULATING SPLICING<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE L'ÉPISSAGE
申请人:[en]REMIX THERAPEUTICS INC.
公开号:WO2023034836A1
公开(公告)日:2023-03-09
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.